Cardio Diagnostics said the final gapfill payment rate of $854 for both tests is an increase from the preliminary gapfill ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
A large international study has shown that a blood biomarker yet to be used in cardiac arrest care can give a clearer picture ...
(MENAFN- EIN Presswire) EINPresswire/ -- GENinCode US Inc the Irvine based predictive genetics company focused on the prevention of coronary heart disease (“CHD” or“Heart Disease”) and risk assessment ...
Most standard check-ups rely on a resting ECG and a lipid panel (cholesterol test). While useful, these are often ...
News Medical on MSN
Blood test reveals prognosis after cardiac arrest: Lancet
A blood biomarker yet to be used in cardiac arrest care can give a clearer picture of the extent of brain damage after a ...
A noninvasive AI tool may be able to predict potential cardiovascular events in patients with suspected stable coronary ...
TipRanks on MSN
GENinCode partners with Sohin Genetics to distribute heart disease risk test in Mexico
An announcement from GENinCode UK Ltd. ( ($GB:GENI) ) is now available. GENinCode has announced a collaboration with Sohin Genetics in Mexico to ...
The issue: Many runners (particularly women) report that their fitness trackers tell them they’re exercising in a higher zone ...
"Obtaining the final rate is a significant step in our efforts to expand access to our advanced cardiovascular tests for Medicare beneficiaries." PrecisionCHD is designed to aid in the diagnosis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback